Aggressive outreach drives Chinese biotech success: McKinsey's Shanghai analyst

China’s biopharmaceutical and biotechnology companies are rapidly expanding their global presence, driven not only by strong drug pipelines but also by increasingly aggressive outreach to international partners, according to a China industry expert. “If you look at the first two months of licensing or cross-border deals from Chinese innovators, the volume has already exceeded that of the first quarter last year,” said Fangning Zhang, a partner at McKinsey & Company’s Shanghai office, in an inter

By The Korea Herald